Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
about
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in SchizophreniaGender-based personalized pharmacotherapy: a systematic review.Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerThe Protective Effect of Alpha 7 Nicotinic Acetylcholine Receptor Activation on Critical Illness and Its MechanismNatural compounds interacting with nicotinic acetylcholine receptors: from low-molecular weight ones to peptides and proteins.Potential serotonergic agents for the treatment of schizophrenia.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.Targeting α7 nicotinic acetylcholine receptors: a future potential for neuroprotection from traumatic brain injury.The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.
P2860
Q34481351-9E28CFA6-5975-4CF6-BB6E-3F4AD241C2E2Q36335289-98AF1AC0-8BDD-476E-A076-6D6AEEED578DQ36881996-1EFAF1CD-F3E8-4414-B200-0C5D6A0FBE21Q37258840-8C31A261-F81E-4F86-8659-8FC96EB0D91FQ37604595-AC88A34F-FB46-45DE-8777-CEF0C45A135FQ38501709-2A1A7C7D-828E-4659-A745-8C5572722347Q38635792-7B782AAA-A82A-481F-896D-3604E6FE0AD8Q38718345-DB7A0FE1-E782-4E4E-8731-6E56F723E1AAQ38929250-4648F8F6-3914-49DF-9E61-5A7107A20E5CQ47127039-7B646784-AC23-4499-972D-FFD4EEE67F40Q47158626-8403705F-5EA3-4703-890A-6B1CBBB720FAQ53404956-7CCB63C3-786F-4AFC-B595-F5089E8B3AE5
P2860
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@ast
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@en
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@nl
type
label
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@ast
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@en
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@nl
prefLabel
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@ast
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@en
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@nl
P2093
P1476
Pharmacodynamics, pharmacokine ...... se and bioavailability studies
@en
P2093
André Van Vliet
Ann J Barbier
Dana C Hilt
Maria Gawryl
Martijn Hilhorst
Michael G Palfreyman
Monica Massaro
Nancy Dgetluck
Renger Tiessen
Wia Timmerman
P304
P356
10.1016/J.CLINTHERA.2014.09.013
P577
2014-10-14T00:00:00Z